Market Closed -
Nasdaq
04:00:00 2024-05-14 pm EDT
|
5-day change
|
1st Jan Change
|
1.28
USD
|
+1.99%
|
|
-7.25%
|
-14.67%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
98.14
|
316.8
|
251.2
|
62.1
|
67.72
|
113
|
-
|
-
|
Enterprise Value (EV)
1 |
98.14
|
189.3
|
176.3
|
-54.27
|
21.04
|
79.93
|
168.6
|
259.8
|
P/E ratio
|
-
|
-5.44
x
|
-2.44
x
|
-0.37
x
|
-0.71
x
|
-1.25
x
|
-1.43
x
|
1.22
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.65
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
1.48
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
10,117
|
20,718
|
26,249
|
44,358
|
45,145
|
90,079
|
-
|
-
|
Reference price
2 |
9.700
|
15.29
|
9.570
|
1.400
|
1.500
|
1.255
|
1.255
|
1.255
|
Announcement Date
|
3/16/20
|
2/26/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
175
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-37.03
|
-48.97
|
-75.42
|
-86.52
|
-99.22
|
-91.02
|
-94.7
|
267.2
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
152.72%
|
Earnings before Tax (EBT)
1 |
-
|
-44.02
|
-92.94
|
-120.4
|
-93.61
|
-96.15
|
-94.92
|
145.3
|
Net income
1 |
-
|
-44.02
|
-92.94
|
-120.4
|
-93.61
|
-99.14
|
-100.1
|
44.98
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
25.7%
|
EPS
2 |
-
|
-2.810
|
-3.930
|
-3.780
|
-2.110
|
-1.002
|
-0.8775
|
1.030
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/16/20
|
2/26/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-22.77
|
-21.44
|
-20.61
|
-20.12
|
-24.36
|
-27.25
|
-25.02
|
-23.57
|
-23.38
|
-23.88
|
-22.33
|
-22.27
|
-22.55
|
-21.98
|
-22.95
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-21.18
|
-20.81
|
-21.9
|
-21.22
|
-56.47
|
-25.27
|
-24
|
-22.77
|
-21.57
|
-29.58
|
-22.22
|
-22.23
|
-22.41
|
-21.98
|
-22.95
|
Net income
1 |
-21.18
|
-20.81
|
-21.9
|
-21.22
|
-56.47
|
-25.27
|
-24
|
-22.77
|
-21.57
|
-29.58
|
-22.58
|
-23.03
|
-23.59
|
-21.98
|
-22.95
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.6000
|
-0.7400
|
-0.7200
|
-0.6900
|
-1.620
|
-0.5800
|
-0.5400
|
-0.5100
|
-0.4800
|
-0.3000
|
-0.2320
|
-0.2340
|
-0.2360
|
-0.2200
|
-0.1850
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/10/22
|
8/4/22
|
11/3/22
|
2/23/23
|
5/11/23
|
8/3/23
|
11/14/23
|
2/22/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
55.5
|
147
|
Net Cash position
1 |
-
|
127
|
74.9
|
116
|
46.7
|
33.1
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
0.07
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/16/20
|
2/26/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
1.255
USD Average target price
11.5
USD Spread / Average Target +816.33% Consensus |
1st Jan change
|
Capi.
|
---|
| -14.67% | 113M | | +5.33% | 111B | | +12.11% | 105B | | -12.56% | 22.34B | | -3.70% | 21.93B | | -6.03% | 18.59B | | -35.21% | 18.12B | | -10.86% | 16.96B | | +5.10% | 13.7B | | +37.57% | 12.45B |
Bio Therapeutic Drugs
|